Vanguard Group Inc. grew its holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 0.9% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 19,661,800 shares of the pharmaceutical company’s stock after acquiring an additional 180,239 shares during the period. Vanguard Group Inc. owned about 0.08% of Vertex Pharmaceuticals worth $3,605,582,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors have also bought and sold shares of the business. Daiwa Securities Group Inc. grew its stake in shares of Vertex Pharmaceuticals by 0.5% in the second quarter. Daiwa Securities Group Inc. now owns 11,806 shares of the pharmaceutical company’s stock worth $2,165,000 after acquiring an additional 61 shares in the last quarter. Signaturefd LLC grew its stake in shares of Vertex Pharmaceuticals by 7.6% in the second quarter. Signaturefd LLC now owns 1,016 shares of the pharmaceutical company’s stock worth $186,000 after acquiring an additional 72 shares in the last quarter. ETF Managers Group LLC grew its stake in shares of Vertex Pharmaceuticals by 9.1% during the first quarter. ETF Managers Group LLC now owns 877 shares of the pharmaceutical company’s stock worth $161,000 after purchasing an additional 73 shares in the last quarter. Pittenger & Anderson Inc. grew its stake in shares of Vertex Pharmaceuticals by 64.7% during the first quarter. Pittenger & Anderson Inc. now owns 191 shares of the pharmaceutical company’s stock worth $35,000 after purchasing an additional 75 shares in the last quarter. Finally, Next Capital Management LLC grew its stake in shares of Vertex Pharmaceuticals by 84.4% during the second quarter. Next Capital Management LLC now owns 166 shares of the pharmaceutical company’s stock worth $30,000 after purchasing an additional 76 shares in the last quarter. Institutional investors and hedge funds own 94.81% of the company’s stock.

NASDAQ VRTX traded down $2.73 during trading hours on Wednesday, hitting $173.27. The company had a trading volume of 76,247 shares, compared to its average volume of 998,918. The company has a debt-to-equity ratio of 0.12, a quick ratio of 3.63 and a current ratio of 3.74. Vertex Pharmaceuticals Incorporated has a 1-year low of $151.80 and a 1-year high of $195.81. The company has a market cap of $44.97 billion, a PE ratio of 61.30, a price-to-earnings-growth ratio of 2.28 and a beta of 1.37. The business has a 50 day moving average of $178.98 and a 200-day moving average of $177.51.

Vertex Pharmaceuticals (NASDAQ:VRTX) last released its quarterly earnings data on Wednesday, July 31st. The pharmaceutical company reported $0.99 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.75 by $0.24. Vertex Pharmaceuticals had a net margin of 64.13% and a return on equity of 21.73%. The company had revenue of $941.29 million during the quarter, compared to the consensus estimate of $884.66 million. During the same quarter in the prior year, the firm posted $0.94 earnings per share. Vertex Pharmaceuticals’s revenue for the quarter was up 25.1% on a year-over-year basis. Sell-side analysts expect that Vertex Pharmaceuticals Incorporated will post 3.41 earnings per share for the current fiscal year.

Vertex Pharmaceuticals declared that its board has initiated a stock repurchase plan on Wednesday, July 31st that authorizes the company to repurchase $500.00 million in shares. This repurchase authorization authorizes the pharmaceutical company to reacquire up to 1.2% of its stock through open market purchases. Stock repurchase plans are usually a sign that the company’s board of directors believes its stock is undervalued.

In other Vertex Pharmaceuticals news, EVP Stuart A. Arbuckle sold 2,155 shares of the company’s stock in a transaction on Friday, August 2nd. The shares were sold at an average price of $177.78, for a total value of $383,115.90. Following the completion of the transaction, the executive vice president now owns 34,395 shares in the company, valued at $6,114,743.10. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Michael Parini sold 2,125 shares of the company’s stock in a transaction on Friday, July 12th. The shares were sold at an average price of $175.27, for a total transaction of $372,448.75. Following the completion of the transaction, the executive vice president now owns 37,128 shares of the company’s stock, valued at approximately $6,507,424.56. The disclosure for this sale can be found here. Insiders sold 35,486 shares of company stock valued at $6,491,637 in the last 90 days. 0.70% of the stock is currently owned by insiders.

VRTX has been the subject of a number of analyst reports. ValuEngine downgraded shares of Vertex Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday, September 10th. HC Wainwright reiterated a “buy” rating and set a $220.00 target price on shares of Vertex Pharmaceuticals in a research note on Thursday, August 1st. Maxim Group reiterated a “hold” rating on shares of Vertex Pharmaceuticals in a research note on Friday, August 2nd. Cowen set a $220.00 target price on shares of Vertex Pharmaceuticals and gave the stock a “buy” rating in a research note on Wednesday, July 31st. Finally, JPMorgan Chase & Co. reiterated a “buy” rating and set a $212.00 target price on shares of Vertex Pharmaceuticals in a research note on Thursday, August 1st. One equities research analyst has rated the stock with a sell rating, nine have given a hold rating and fourteen have given a buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus target price of $210.68.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene.

Read More: What is the definition of a trade war?

Want to see what other hedge funds are holding VRTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX).

Institutional Ownership by Quarter for Vertex Pharmaceuticals (NASDAQ:VRTX)

Receive News & Ratings for Vertex Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.